ArticleMedical oncology (Northwood, London, England)2013
Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review.Clinical epigenetics · 2020Pooled it
- The importance of stool DNA methylation in colorectal cancer diagnosis: A meta-analysis.PloS one · 2018Pooled it
- Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.Journal of gastrointestinal cancer · 2016Pooled it
- The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer: A Systematic Review and Meta-Analysis.Medicine · 2016Pooled it
- Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- Role of fibrilins in human cancer: A narrative review.Health science reports · 2023Article
- Pre-diagnostic blood biomarkers for adult glioma.Frontiers in oncology · 2023Review
- The extracellular matrix glycoprotein fibrillin-1 in health and disease.Frontiers in cell and developmental biology · 2023Review
- The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.Cancer communications (London, England) · 2022Article
- Article
- Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.Frontiers in genetics · 2022Review
- New Studies of the Aberrant Alterations in Fibrillin-1 Methylation During Colorectal Cancer Development.Frontiers in oncology · 2022Article
- A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer.Oncology letters · 2021Article
- Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer.Frontiers in cell and developmental biology · 2021Review
- A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample.Journal of Cancer · 2021Article
- Identification of key genes involved in the development and progression of early-onset colorectal cancer by co-expression network analysis.Oncology letters · 2020Article
- Article
- Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.Cancer biomarkers : section A of Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prior studies have demonstrated that analysis of gene promoter methylation in stool samples may be a potential biomarker for noninvasive colorectal cancer detection. Aberrant methylation in gene promoter is common in various cancers, and epigenetic alterations can result in down-regulation or silence of gene expression. Recently, hypermethylation of fibrillin-1 (FBN1) was reported to be associated with colorectal cancer (CRC). In this study, we examined the methylation status of FBN1 in stool samples to test CRC. For the purpose of colorectal cancer detection, we investigated FBN1 hypermethylation in the tissue and stool samples of colorectal cancer patients using methylation-specific polymerase chain reaction. The result is that out of 75 patients with colorectal cancer, 59 (78.7%) exhibited hypermethylated FBN1 in their tumor tissue DNA. We next detected the methylation status of FBN1 in the stool DNA of these patients. The hypermethylated FBN1 occurred in 72% (54/75) of these patients in their stool samples and occurred in 6.7% (2/30) of healthy people (P < 0.001). The results indicated 72.0% sensitivity and 93.3% specificity of the test for detecting CRC by using stool samples. So, the study reveals that hypermethylation status in the promoter of FBN1 is a high specific and sensitive biomarker for colorectal cancer, and detecting hypermethylated FBNI in stool samples is a noninvasive and useful method for screening colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.